Pharvaris N.V. (PHVS)
14.51
0.51 (3.64%)
At close: Apr 21, 2025, 3:59 PM
14.44
-0.50%
After-hours: Apr 21, 2025, 04:07 PM EDT
3.64% (1D)
| Bid | 13.62 |
| Market Cap | 790.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -134.22M |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -5.18 |
| Forward PE | -4.29 |
| Analyst | Buy |
| Ask | 15 |
| Volume | 35,868 |
| Avg. Volume (20D) | 40,401 |
| Open | 13.81 |
| Previous Close | 14.00 |
| Day's Range | 14.00 - 14.68 |
| 52-Week Range | 11.51 - 25.50 |
| Beta | -2.84 |
About PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 108
Stock Exchange NASDAQ
Ticker Symbol PHVS
Website https://pharvaris.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 203.24% from the latest price.
Stock Forecasts
